Quinidine    (DrugBank: Quinidine)

3 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis3
8Huntington disease1
13Multiple sclerosis/Neuromyelitis optica6

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 508 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03883581
(ClinicalTrials.gov)
July 25, 201912/3/2019Impact of Nuedexta on Bulbar Physiology and Function in ALSImpact of Nuedexta on Bulbar Physiology and Function in ALSAmyotrophic Lateral SclerosisDrug: dextromethorphan HBr and quinidine sulfateUniversity of FloridaHoly Cross Hospital, Florida;ALS AssociationRecruiting18 Years90 YearsAll40Phase 1;Phase 2United States
2NCT00573443
(ClinicalTrials.gov)
December 200713/12/2007Safety and Efficacy of AVP-923 in PBA Patients With ALS or MSA Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)Pseudobulbar Affect (PBA)Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Drug: PlaceboAvanir PharmaceuticalsINC ResearchCompleted18 Years80 YearsAll326Phase 3United States;Argentina;Brazil
3NCT00021697
(ClinicalTrials.gov)
January 20011/8/2001Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALSA Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: AVP-923Avanir PharmaceuticalsNULLCompleted18 Years80 YearsBoth100Phase 3United States

8. Huntington disease    [ 197 clinical trials,   171 drugs,   (DrugBank: 54 drugs),   82 drug target genes,   144 drug target pathways]
Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 197 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03854019
(ClinicalTrials.gov)
August 5, 201922/2/2019Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's DiseaseEvaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's DiseaseHuntington Disease;IrritabilityDrug: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg);Drug: PlaceboThe University of Texas Health Science Center, HoustonCures Within ReachRecruiting18 Years75 YearsAll22Phase 3United States

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-002178-22-GB
(EUCTR)
27/04/201229/03/2012A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple SclerosisA Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis Central Neuropathic Pain in Multiple Sclerosis
MedDRA version: 14.1;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Avanir Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Czech Republic;Argentina;Spain;Poland;Bulgaria;Germany;United Kingdom
2EUCTR2011-002178-22-PL
(EUCTR)
20/03/201225/11/2011A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple SclerosisA Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis Central Neuropathic Pain in Multiple Sclerosis
MedDRA version: 15.1;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Avanir Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Czech Republic;Argentina;Spain;Poland;Bulgaria;Germany;United Kingdom
3EUCTR2011-002178-22-CZ
(EUCTR)
08/02/201202/11/2011A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple SclerosisA Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis Central Neuropathic Pain in Multiple Sclerosis
MedDRA version: 14.1;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Product Name: Dextromethorphan/Quinidine
Product Code: AVP-923
INN or Proposed INN: DEXTROMETHORPHAN HYDROBROMIDE
Other descriptive name: N/A
INN or Proposed INN: Quinidine Sulfate
Other descriptive name: N/A
Avanir Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Czech Republic;Argentina;Spain;Poland;Bulgaria;Germany;United Kingdom
4EUCTR2011-002178-22-ES
(EUCTR)
26/12/201131/10/2011A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple SclerosisA Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis Central Neuropathic Pain in Multiple Sclerosis
MedDRA version: 14.0;Level: LLT;Classification code 10054095;Term: Neuropathic pain;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Dextrometorfano/Quinidina
Product Code: AVP-923
INN or Proposed INN: DEXTROMETORFANO HIDROBROMURO
Other descriptive name: N/A
INN or Proposed INN: Quinidina sulfato
Other descriptive name: N/A
Product Name: Dextrometorfano/Quinidina
Product Code: AVP-923
INN or Proposed INN: DEXTROMETORFANO HiDROBROMURO
Other descriptive name: N/A
INN or Proposed INN: Quinidina sulfato
Other descriptive name: N/A
Product Name: Dextrometorfano/Quinidina
Product Code: AVP-923
INN or Proposed INN: DEXTROMETORFANO HIDROBROMURO
Other descriptive name: N/A
INN or Proposed INN: Quinidina sulfato
Other descriptive name: N/A
Avanir Pharmaceuticals, Inc.NULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Czech Republic;Argentina;Poland;Spain;Bulgaria;United Kingdom
5NCT01324232
(ClinicalTrials.gov)
September 201123/3/2011Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple SclerosisA Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients With Multiple SclerosisCentral Neuropathic Pain;Multiple SclerosisDrug: AVP-923;Drug: PlaceboAvanir PharmaceuticalsNULLCompleted18 Years85 YearsAll200Phase 2United States;Argentina;Czechia;Poland;Spain;Czech Republic;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00573443
(ClinicalTrials.gov)
December 200713/12/2007Safety and Efficacy of AVP-923 in PBA Patients With ALS or MSA Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)Pseudobulbar Affect (PBA)Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Drug: PlaceboAvanir PharmaceuticalsINC ResearchCompleted18 Years80 YearsAll326Phase 3United States;Argentina;Brazil